Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, address the critical clinical challenges in treating atopic dermatitis (AD) patients and discuss current trends in biologics use for AD.

Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.

The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.

Medical experts discuss the long-term consequences of extended use of topical corticosteroids or calcineurin inhibitors in atopic dermatitis (AD) patients and recommend appropriate monitoring strategies.

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.

The panel delves into the most challenging symptoms of atopic dermatitis (AD), maps out the patient journey, and highlights crucial factors in effectively managing itch and other AD-related symptoms.

Atopic dermatitis experts examine factors that impact coverage decisions for atopic dermatitis (AD) treatments, address challenges providers encounter (such as step-therapy and prior authorization) and offer strategies to streamline the prior authorization process for topical AD therapies.

In their concluding remarks, the expert panel shares insights and provides recommendations to help practicing clinicians optimize atopic dermatitis patient care.